Effect observation of insulin pump combined with dipeptidyl peptidase-Ⅳ inhibitor on the treatment of newly diagnosed type 2 diabetes mellitus
- VernacularTitle:胰岛素泵联合二肽基肽酶-Ⅳ抑制剂治疗新发2型糖尿病的疗效观察
- Author:
Yingzi CHEN
1
;
Xinlong MENG
;
Peng DU
;
Congqing MIU
;
Aijuan FAN
;
Jingjing LIU
;
Dechuan LU
Author Information
- Keywords: type 2 diabetes mellitus; insulin pump; dipeptidyl peptidase-Ⅳ; pancreatic β cell function index; insulin resistance index; C-peptide
- From: Journal of Clinical Medicine in Practice 2019;23(8):22-24
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the effect of insulin pump combined with dipeptidyl peptidase-Ⅳ (DPP-Ⅳ) inhibitor on the treatment of newly diagnosed type 2 diabetes mellitus (T2 DM). Methods Totally 51 newly diagnosed patients with T2 DM were randomly divided into experimental group (insulin pump combined with DPP-Ⅳ inhibitor) and control group (insulin pump alone). After 15 days of treatment, the clinical effect was compared between two groups. Results After treatment, the blood sugar related indexes in both groups significantly improved (P ＜ 0. 05), and the blood sugar control of the experimental group was significantly better than that of the control group (P ＜ 0. 05). The pancreatic β cell function index, area under curve of C-peptide and insulin resistance index in the experimental group were significantly better than those in the control group (P ＜0. 05). The dosage of insulin, the ratio of patients with blood sugar reaching the standard completely, the time of blood sugar reaching the standard and the increase value of body mass in the experimental group were significantly better than those in the control group (P ＜ 0. 01). The incidence rate of hypoglycemia was 8. 00％ (2/26) in the experimental group and 12. 00％ (3/25) in the control group, and there was no significant difference between the two groups (P＞ 0. 05). During the treatment, no severe hypoglycemic events and liver and kidney function damage occurred in both groups. Conclusion Insulin pump combined with DPP-Ⅳ inhibitor is effective in the treatment of newly diagnosed T2 DM, which can effectively control blood sugar, reduce insulin resistance and weight gain.
